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 Hereditary haemochromatosis is a common autosomal recessive disorder of iron 
overload in Caucasian populations. Clinical manifestations usually occur in individuals 
homozygous for the C282Y mutation in the HFE gene product and who have developed 
significant iron loading. Current screening methods can detect affected individuals either prior 
to, or early during, disease evolution, enabling early introduction of phlebotomy treatment that 
can normalise life expectancy. Evaluation of possible iron overload, via measurement of serum 
transferrin saturation and ferritin level, is the most appropriate initial test for those subjects 
presenting clinically for evaluation. HFE genotyping, when combined with serum biochemical 
measurements, defines the presence of likely iron overload and the underlying genetic disorder 
and is the preferred initial screening modality for families of an affected individual. Definitive 
proof of iron overload requires measurement of hepatic iron concentration or total iron burden 
via therapeutic phlebotomy – elevated serum ferritin level alone is not adequate. We now 
recognize that the natural history of HH is not as discrete as previously believed, because 
genetic and environmental modifiers of disease penetrance are increasingly identified as 
influencing the clinical expression of HH. In fact, a minority of C282Y homozygotes develop 
classical “iron overload disease”, although it has recently emerged that the disorder may 
predispose to breast and colorectal cancer. Uncertainties as to the true clinical impact of the 
condition at a population level lead to current recommendations of cascade screening of 
families of affected patients, case-finding in high-risk groups, such as patients with clinical 
manifestations consistent with the diagnosis, and a high level of clinical awareness in the 




Hereditary haemochromatosis (HH) is a common inherited disorder of iron metabolism 
affecting individuals primarily of northern European descent, which can result in iron overload, 
tissue injury and disease in a variable proportion of affected individuals. Whilst iron overload 
can result from a variety of primary or secondary causes (Table 1), the term HH is restricted to 
defining iron overload disease which results from mutations in a limited range of key iron 
metabolism genes: Type 1 HH (HFE gene mutations), Type 2 (hepcidin or haemojuvelin gene 
mutations), Type 3 (transferrin receptor 2 gene mutations), and Type 4 (ferroportin gene 
mutations). The mechanisms responsible for the production of iron overload in the presence of 
these various types of HH are reviewed elsewhere,
1
 sufficed to say that all result in impaired 
production of the key iron regulatory hormone hepcidin, impaired iron sensing and 
consequential inappropriately increased iron absorption from the gastrointestinal tract and 
release of iron from the bone marrow iron stores. 
For the purposes of this article we will hereafter only refer to HFE-related HH. In order 
to discuss screening for HH, it is first necessary to understand the natural history and clinical 
expressivity of HH. 
DISCOVERY AND CHARACTERISATION OF HFE-RELATED HH 
During the latter years of the 20
th
 century, intensive genetic research led to the 
discovery of the candidate gene responsible for the majority of cases of for HH, termed HFE.
2
 
Two common mutations were identified in the gene product: first, tyrosine was substituted for 
cysteine at amino acid 282 (C282Y) and second, aspartate was substituted for histidine at 
amino acid 63 (H63D). Homozygosity for C282Y was observed in 85% to 90% of patients of 
northern European origin with typical HH,
2-5
 although it was relatively rare in non-Caucasian 
populations.
6
 The C282Y mutation in the HFE gene product occurs in 1 in 7 individuals of 
northern European descent with 1 in 200 being homozygous for the mutation.
7
 The more 
common H63D mutation, either alone or in homozygous form, has not been shown to be 




Following the initial discovery of the HFE gene, several cross-sectional studies 
indicated a wide variation in the biochemical penetrance of the disorder, as evidenced by 
elevated serum ferritin levels. When stratified according to gender, biochemical iron overload 
was found in 70% to 88% of men and 30% to 60% of women homozygous for the C282Y 
mutation.
3,6-9
 High clinical penetrance was found in the original cross-sectional population 
study in Busseleton, Western Australia. Clinical penetrance (defined as hepatomegaly, skin 
pigmentation, or arthropathy) was present in 50% of C282Y homozygous subjects.
5
 Twenty-
five percent of C282Y homozygotes had hepatic fibrosis and 10% had cirrhosis on liver biopsy. 
Interestingly, 25% of the homozygotes had no clinical symptoms or overt signs, with 
corresponding normal range serum ferritin over 4 years of follow-up.  
A large Norwegian population-based study of more than 65,000 individuals aged 20 
years or older reported a similar incidence of C282Y homozygosity as the Australian study, but 
clinical penetrance was lower.
10
 Liver biopsy-proven moderate fibrosis and/or cirrhosis were 
seen in only 10% of cases. Fatigue and joint pain were the most common extrahepatic 




A French clinic-based study also confirmed that 0.5% of the population were 
homozygous for C282Y, consistent with the earlier studies.
9
 Ninety percent of male C282Y 
homozygotes had at least one clinical symptom compared with 60% of females. Family history 
of iron excess and chronic fatigue were common clinical features for both genders. Twenty 
percent of homozygous subjects had arthritis, and 5% to 10% had diabetes or increased alanine 
transaminase levels.  
Adams et al. showed in a study of 99,711 North American subjects that the prevalence 
of C282Y mutation was highest in whites (0.44 %) and lowest in Asians (0.000039%). Self-




Contrary to the relatively high clinical expression in other population studies, Beutler et 
al.,
8
 in a study of 41,000 patients recruited from health appraisal clinics, reported that less than 
1% of C282Y homozygotes developed an overt clinical phenotype. However, the majority of 
clinically presenting C282Y homozygotes diagnosed prior to the commencement of this study 
were excluded from the analysis. Plasma type IV collagen was used as a surrogate of hepatic 
fibrosis and indicated that up to 25% of subjects might have liver fibrosis, although no 
statistically significant relationship was seen between collagen type IV and serum ferritin 
concentrations. Surprisingly, symptoms that represent the common clinical features of HH were 
no more prevalent in C282Y homozygotes than in controls.  
It was clear from the cross-sectional population studies performed prior to 2005 that the 
clinical expressivity of HH was highly variable and most likely changed with time. Thus, 
resolution of the true natural history of progression of HH would require longitudinal 
studies.
11,12
 Olynyk et al. followed the fate of 12 untreated C282Y homozygotes over 17 years. 
Whilst the median transferrin saturation increased from 42% to 76%, serum ferritin levels 
varied markedly. Fifty percent of C282Y homozygotes who underwent liver biopsy at the end 
of follow-up had advanced fibrosis with concurrent serum ferritin levels exceeding 500 µg/L. 
Clinically, only one patient had diabetes in 1981 and by the end of the study, arthritis 
developed in 4 of 12 patients, and hepatomegaly in 2 of 12 patients.
13
 Similar findings were 
reported by Andersen et al. in a study of 23 untreated C282Y homozygotes over a period of 25 
years, and none developed clinically overt hemochromatosis.
14
  
In 2006, the US Preventive Health Services Task Force systemically reviewed HH and 
concluded that larger longitudinal studies would be required to consolidate understanding of the 
natural history of disease and the marked variance in clinical expression in terms of putative 
genetic and environmental modifiers.
15
 These issues were comprehensively addressed by a 
series of Australian studies conducted on 31,192 persons of Northern European descent who 
were part of the prospective longitudinal study known as the Melbourne Collaborative Cohort 
Study.
16-18
 This cohort was recruited between 1990 and 1994 through the Australian electoral 
roll, community announcement, and advertisement. At initial recruitment, the mean age of 
subjects was 55 years. Participants underwent baseline clinical assessment and biochemical 
evaluation. HFE genotyping of 31,192 baseline samples was performed. From this cohort, 1438 
subjects, including all C282Y homozygotes and a stratified random sample of subjects from the 
remaining groups with other HFE genotypes, were evaluated in a follow-up study 12 years 
after initial recruitment. There were 203 C282Y homozygotes, 242 compound heterozygotes, 
337 C282Y heterozygotes, and 147 H63D heterozygote/homozygotes identified. At baseline, 
84% of male and 65% of female C282Y homozygotes had elevated serum ferritin levels, and 
37% of male and 3% of female HH C282Y homozygotes had ferritin levels exceeding 1000 
µg/L.
16,19
 C282Y homozygous males had up to a 50% likelihood of progression to serum 
ferritin levels exceeding 1000 µg/L after 12 years if they had baseline serum ferritin values of 
300 to 1000 µg/L. With similar baseline values, C282Y homozygous females had up to a 20% 
likelihood of progression to serum ferritin levels exceeding 1000 µg/L after 12 years. For both 
genders, the risk of biochemical progression over a 12-year period to ferritin levels exceeding 
1000 µg/L was less than 15% if they had normal baseline serum ferritin values.
16,18
 
Furthermore, C282Y homozygotes who were likely to develop serum ferritin levels sufficient 
to place them at risk of iron overload–related disease generally did so by the age of 55 years.  
The term “iron overload–related disease” was introduced by Allen et al.
16
 in 2008 to 
define the presence of documented iron overload combined with clinical sequelae (cirrhosis, 
liver fibrosis, hepatocellular carcinoma, elevated aminotransferase levels, physician-diagnosed 
symptomatic hemochromatosis, or arthropathy of the second and third metacarpophalangeal 
joints). It is now clear that definitive diagnosis of iron overload requires more than 
measurement of serum ferritin levels.
1,20,28
 Elevated serum ferritin levels may occur in multiple 
conditions, other than HH, where there is no correlation between hepatic iron stores and the 
ferritin level.
20,21,28
 Definitive diagnosis of iron overload requires direct measurement of hepatic 
iron concentration or retrospective assessment of iron overload through quantitative 
phlebotomy therapy.
1
 Direct measurement of hepatic iron concentration is achieved 
noninvasively through R2 magnetic resonance imaging 
22
 or liver biopsy.
1
 
Fatigue, liver disease, and increased levels of aminotransferase are more prevalent in 
male C282Y homozygotes with ferritin levels exceeding 1000 µg/L compared with other HFE 
genotypes.
16
 C282Y homozygous subjects with serum ferritin levels less than 1000 μg/L did not 
have increased symptoms or signs of iron overload disease in comparison to wild-type individuals 
or C282Y homozygotes who possessed normal iron studies.
23
 Iron overload–related disease was 
present in 28% of untreated men and 1% of untreated women at the age of 65 years. Recent 
studies have clearly demonstrated that a classical arthropathy is associated with HH, and occurs in 
up to 24% of individuals, especially when the serum ferritin level exceeds 1000 μg/L.
24
 A 
common theme to emerge from many population studies is that a threshold value for serum ferritin 
levels exceeding 1000 µg/L identifies those at highest risk of significant iron overload 
complications, especially liver fibrosis and cirrhosis.
3,25-27
 Significant iron overload occurs when 
the hepatic iron concentration is elevated to greater than 3-times the upper limit of normal (greater 
than 90 μmol/g dry weight).
28
 Liver fibrosis is reversible with phlebotomy therapy,
26
 underscoring 
the importance of diagnosis and initiating phlebotomy therapy before cirrhosis becomes 
established. 
Apart from primary liver cancer, C282Y and H63D mutations have been implicated in 
development of extrahepatic cancers. H63D homozygosity was shown to be a genetic modifier 
of carcinogenesis in hereditary nonpolyposis colorectal cancer, where it results in a three-fold 
increased risk of cancer in MMR gene mutation carriers and earlier onset of cancer.
29
 C282Y 
homozygosity results in a two-fold increased risk of breast cancer in women 
30,31
 and colorectal 
cancer in men and women.
30
 Adding further to the emerging evidence base supporting a role 
for iron as a cofactor in carcinogenesis, Zacharski et al. 
32
 showed that a mild reduction of iron 
stores in normal individuals is associated with a reduced risk of cancer. 
The risk of iron overload–related disease in C282Y/H63D compound heterozygotes is 
substantially less than that of C282Y homozygotes. Gurrin et al. 
17,18
 reported a longitudinal 12-
year clinical follow-up study of 180 untreated compound heterozygotes (84 males) compared 
with 330 randomly selected wild-type control subjects. Compared with controls, mean serum 
ferritin levels and transferrin saturation were significantly higher for both genders, although 
both were within normal ranges, consistent with earlier reports.
3,33
 Serum ferritin levels did not 
increase significantly in male or postmenopausal female compound heterozygotes after middle 
age. Only one male subject (who also had other liver disease risk factors) and none of the 
female subjects developed iron overload–related disease.   
SCREENING FOR HH  
The “gold standard” criteria for determination of appropriateness of generalised 
population screening for a disease have been defined by the World Health Organisation as: 
34
 
1. The condition sought should be an important health problem for the individual and 
community 
2. The natural history of the disease should be adequately understood 
3. There should be a latent or early symptomatic stage 
4. There should be a suitable and acceptable screening test or examination 
5. There should be an accepted treatment or useful intervention for patients with the 
disease 
6. Facilities for diagnosis and treatment should be available 
7. There should be an agreed policy on whom to treat as patients 
8. Treatment started at an early stage should be of more benefit than treatment started 
later. 
9. The cost should be economically balanced in relation to possible expenditure on 
medical care as a whole 
10. Case finding should be a continuing process and not a once and for all project. 
 
Hereditary haemochromatosis complies with most, but not all, of the screening criteria, 
as discussed below. A key issue relates to which population to screen: HH is a disorder limited 
to populations of northern European descent. Iron overload diseases also occur in other ethnic 
groups, and thus detection needs to be considered in the light of ethical decisions regarding 
allocation of medical resources, particularly in ethnically diverse populations such as those that 
exist now in many nations that were originally historically based on northern European 
migration. 
Criterion 1. Whilst C282Y homozygosity is very common, disease sequelae which are 
required to meet the definition of HH are far less common. There is no doubt that some subjects 
with HH if left untreated can progress to serious disease which can be fatal.
1
 Although the 
natural history of the disease is well understood, clinical penetrance is heavily influenced by 
genetic and environmental factors. At most, about 1% of female and 30% of male C282Y 
homozygous subjects will develop iron overload disease.
16-18
 This equates to 1 in 20,000 
females and 1 in 670 males of northern European origin suffering from iron overload disease 
consequential to C282Y homozygosity. The impact of the increased propensity to malignancy 
at a population level which is incurred through C282Y homozygosity remains to be defined. 
Criterion 2. Multiple studies demonstrate that the natural history is not completely 
predictable. Less than 15% of adult C282Y homozygotes who possess normal serum ferritin 
levels will progress to ferritin levels greater than 1000 μg/L. Up to 80% of females and 50% of 
males who possess serum ferritin levels of at least 1000 μg/L will show reductions of ferritin 
levels in the absence of treatment over a 12-year time-frame. 
18
 
Criteria 3 and 4. Hereditary haemochromatosis has a long, asymptomatic latent period 
during which genetic testing for HFE mutations and serum iron studies (transferrin saturation 
and ferritin level) can be used to identify those individuals most at risk of iron overload disease. 
By the age of 55 years, 84% of male and 65% of female C282Y homozygotes will develop 
elevated serum ferritin levels, and 37% of male and 3% of female HH C282Y homozygotes 
will develop ferritin levels exceeding 1000 µg/L.
16,18
 Symptoms and signs of iron overload 
disease are most likely in those whose ferritin levels exceed 1000 µg/L. 
Criteria 5, 6, 7 and 8. Phlebotomy therapy for HH was first described in 1950 and has 
remained the cornerstone of therapy.
35
 In many countries the blood transfusion services provide 
therapeutic phlebotomy and the blood can be utilized for various products. There are no 
evidence-based guidelines on therapeutic phlebotomy for HH. Treatment is conventionally 
commenced once serum ferritin exceeds the normal range; 200 g/L in premenopausal women 
and 300 g/L in postmenopausal women and men. The goal is to reduce the serum ferritin level 
to low normal range, usually 20 – 100 g/L. In the induction phase, 1 unit (400-500 mls) of 
blood, equivalent to 200-250 mg of iron, can be safely removed weekly. Serum ferritin should 
be monitored after each 1-2 g of iron removed. Patients then undergo maintenance phlebotomy, 
which varies between individuals in frequency of requirement to keep serum ferritin levels in 
the range 20-100 g/L.
36-40




The benefit of phlebotomy has been clearly demonstrated in cohort studies.
42-46
 Survival 
of clinically diagnosed HH patients who have undergone phlebotomy therapy is greater than 
those who are not adequately de-ironed.
42
 It is also thought that pre-emptive therapy prevents 
complications, although treatment efficacy has never been subjected to randomized controlled 
studies. In the absence of complications of cirrhosis or diabetes, the life expectancy of treated 
patients approaches is similar to that of the age and gender-matched general population.
44,45
 
Phlebotomy improves liver transaminases, skin pigmentation and liver fibrosis. Up to 50% of 
patients with biopsy proven liver fibrosis show regression with optimal effect occurring when 
baseline fibrosis is mild.
26,39
 Extra-hepatic manifestations such as hypogonadism, cirrhosis, 
deforming arthropathy and diabetes requiring insulin are usually irreversible.
46
 Phlebotomy is 
generally accepted as being indicated in homozygotes with ferritin levels >1000 g/L.
18
 Recent 
studies indicate that progression of iron overload is not universal. In males, the highest risk of 
progression is in those subjects with ferritin levels > 1000g/L and transferrin saturation > 
95%.
18
 Females have a much lower risk of progression, with the likelihood being 
predominantly influenced by menopausal status. 
The current AASLD guidelines advocate regular phlebotomy to maintain the serum 
ferritin between 50 and 100 g/L in asymptomatic individuals with homozygous HH, markers 
of iron overload, and histological evidence of potentially toxic levels of hepatic iron.
40
 
However, more recent Australian data suggests an alternative approach might be to monitor HH 
subjects with serum ferritin levels between the upper limit of normal and 1000 g/L.
16,18
 These 
studies demonstrated that the risk of development of iron-overload disease in C282Y 
homozygous subjects with ferritin levels in the range between upper limit of normal and 1000 
g/L was no greater than that observed in C282Y homozygotes with normal ferritin or wild-
type controls.
17,18
 Less that 50% of male C282Y homozygotes and less than 20% of female 
C282Y homozygotes with serum ferritin levels less than 1000g/L at the age of 55 years 
progress to levels greater than 1000g/L by the age of 67 years.
18
  
 Criterion 9. The ultimate determinant of implementation of a publicly funded screening 
program is cost. There is no doubt that genetic and/or biochemical screening will discover 
C282Y homozygotes at various stages of disease evolution, some of whom will benefit from 
early intervention. Early cost-effectiveness modeling attempts were based on higher levels of 
disease expression than is apparent from the more recent population studies.
16,47,48
  
 Cascade screening of male individuals within affected families following the initial 
diagnosis of a proband has been demonstrated to be the most cost-effective strategy (41,000 
€/life year gained (LYG)), whereas sequential population screening using either biochemical or 
genetic testing cost in the order of 124,000 or 161,000 €/LYG, respectively.
49
 Screening within 
families provides a 25% likelihood of returning other affected individuals.
49-51
 Gagne et al 
(2007) concluded that provided there was at least 70% biochemical expression with subsequent 
development of clinical sequelae in 5% of these individuals, screening was cost-effective.
48
 
These assumptions most closely reflect the natural history of disease progression in males.
16
 
Due to the limited expressivity in females compared with males, Phatak et al (2008) also 
recommended screening be focused on males over the age of 25 years and of northern 
European descent, or those with a family history of HH.
47
  
 A high level of clinical awareness which leads to “case-finding” for HH is advocated in 
individuals presenting with clinical manifestation known to be associated with HH. These 
include chronic liver disease, diabetes mellitus and arthritis.
1,16
 Routine screening per se has 
not been proven to be beneficial in subjects with diabetes mellitus.
52
 Up to 24% of subjects 




 In summary, true “screening” is currently advocated only in the setting of cascade 
screening of families. Thereafter, males of northern European origin should be considered a 
risk group that is worthy of close scrutiny for assessment of iron status during early to mid 
adult life, often in the setting of routine clinical assessments. A high level of awareness of the 
clinical manifestations of HH, together with the high variability of clinical expressivity, is 
required to guide clinicians in the appropriate detection of affected HH individuals in the most 
timely fashion. 
  
Table 1.   Classification of iron overload states 
 
Hereditary Haemochromatosis 
Type 1  (HFE-related) 
C282Y homozygous (common, high risk for iron overload) 
C282Y/H63D compound heterozygous (common, low risk for iron overload) 
Other HFE mutations (common, low risk for iron overload) 
Type 2  (juvenile hemochromatosis) 
A. hemojuvelin (HJV) mutations (rare, high risk for iron overload) 
B. hepcidin (HAMP) mutations (rare, high risk for iron overload) 
Type 3  (TFR2 mutations) (rare, high risk for iron overload) 
Type 4  (ferroportin mutations) (rare, high risk for iron overload) 
A. loss-of-function  
  B. gain-of-function 
Secondary Iron Overload 
Iron-loading anemias 
Parenteral iron overload 
Long-term hemodialysis 
Chronic liver disease 
 Alcoholic liver disease 
 Hepatitis B or C 
 Porphyria cutanea tarda 
 Nonalcoholic steatohepatitis  
Miscellaneous 
Congenital alloimmune hepatitis (neonatal iron overload) 
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